This Month's Tiny Gems - October 2013
Boston Therapeutics, Inc. (BTHE)
Boston Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes.
Calpian, Inc. (CLPI)
Calpian, Inc. has forged a powerful combination of steady cash flow here in the U.S. on the one hand, and explosive growth potential abroad in India on the other. Both business units are growing fast and creating huge value that has so far gone largely overlooked due to the company’s rapid rise.
CytRx Corp. (NASDAQ:CYTR)
CytRx Corp., a biopharmaceutical research and development company, specializes in the enhanced delivery of proven oncology therapies to treat cancer. The company’s novel linker platform technology can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites while minimizing side effects.
Galena Biopharma, Inc. (NASDAQ:GALE)
Galena Biopharma is focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company’s peptide vaccine immunotherapies harness the patient’s own immune system to identify and destroy cancer cells. Utilizing peptide immunogens has many clinical advantages, including an excellent safety profile and long-lasting protection through immune system activation and convenient delivery.